Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Esp Quimioter ; 29(3): 155-8, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27084880

ABSTRACT

OBJECTIVE: Streptococcus bovis includes variants related to colorectal cancer and non-urinary infections. Its role as urinary pathogen is unknown. Our objective was to assess the presence of urinary infection by S. bovis, analysing the patients and subsequent clinical course. METHODS: Observational study, with longitudinal data collection, performed at our centre between all the cultures requested between February and April 2015. Clinical course of the patients and response to treatment were analysed. RESULTS: Two thousand five hundred and twenty urine cultures were analysed, of which 831 (33%) had a significant microbial count. S. bovis was isolated in 8 patients (0.96%). In 75% of these cases the urine culture was requested because of urinary tract infection symptoms; the remaining 25% because of fever of uncertain source; during the follow-up period no evidence of cancer or endocarditis was detected. S. gallolyticus subspecie pasteurianus was the only variant observed (100%). The clinical response to initial treatment was favourable in all cases. CONCLUSIONS: S. bovis bacteriuria may have clinical significance, especially when S. gallolyticus subspecies pasteurianus is isolated in cases with underlying urinary tract disease.


Subject(s)
Streptococcal Infections/microbiology , Streptococcal Infections/urine , Streptococcus bovis/drug effects , Urinary Tract Infections/microbiology , Urinary Tract Infections/urine , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacterial Load , Female , Fever/microbiology , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Streptococcal Infections/drug therapy , Survival Analysis , Treatment Outcome , Urinary Tract Infections/drug therapy
2.
Transplant Proc ; 45(10): 3620-3, 2013.
Article in English | MEDLINE | ID: mdl-24314976

ABSTRACT

BACKGROUND: Infectious disease, a complication favored by immunosuppression, is the main cause of 1st-year mortality in solid organ transplantation. In renal transplant recipients (RTRs), urinary tract infection (UTI) is the most common, and the microorganisms that are isolated depend on chronology. METHODS: We present an observational study comprising 129 RTRs from January 2010 to December 2011 who were followed during the 1st year after transplantation. We analyzed occurrence of infections, predisposing factors, timing, severity, site of infection, and microorganisms. RESULTS: The patients had a total of 424 infectious episodes during the 1st year (3.29 episodes/patient/year). The predominant focus was the urinary tract, with at least 1 episode in 69.8% of patients. Bacteremia was recorded in 25.6% of patients and surgical wound infection in 20.9%. Cytomegalovirus infection or disease was diagnosed in 46.5%. Severe infections occurred in 30.2%. The predominant pathogen was E. coli. There was a significant correlation between hospital stay and the number of infections (P = .000; r = 0.407) and between body mass index and hospital stay (P = .001; r = 0.282). Severe infections were more frequent in diabetics, patients with a double-J stent, and those treated with basiliximab. Patients with cytomegalovirus replication had a higher number of infections (4.1 ± 1.2 vs 2.5 ± 5; P = .000) and significantly higher annual serum creatinine (1.65 ± 5.7 vs 1.31 ± 1.3 mg/dL; P = .003). CONCLUSIONS: The prevalence of infections in the 1st year after kidney transplantation is very high, occurring mainly in the early period, in the urinary tract, and due to E. coli. Cytomegalovirus replication is associated with a higher number of infections and higher serum creatinine at 1 year. Body mass index is a predictor of early infection and of bacteremia in the post-transplantation period. Basiliximab induction and having a double-J stent were predictors of severe infections.


Subject(s)
Communicable Diseases/epidemiology , Kidney Transplantation/adverse effects , Adult , Antibodies, Monoclonal/adverse effects , Basiliximab , Biomarkers/blood , Body Mass Index , Communicable Diseases/diagnosis , Communicable Diseases/microbiology , Communicable Diseases/virology , Creatinine/blood , Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/virology , Diabetes Complications/etiology , Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Humans , Immunosuppressive Agents/adverse effects , Length of Stay , Male , Prevalence , Recombinant Fusion Proteins/adverse effects , Risk Factors , Severity of Illness Index , Spain , Stents/adverse effects , Time Factors , Treatment Outcome , Urinary Tract Infections/epidemiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...